온콜리틱스 바이오테크(ONCY)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.77 (+0.00%), 시가총액 $106.84M, 52주 범위 $0.33 ~ $1.42.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
온콜리틱스 바이오테크의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
온콜리틱스 바이오테크의 현재 주가는 $0.77 (+0.00%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
온콜리틱스 바이오테크의 시가총액은 약 $106.84M입니다.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.